Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 14 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

21%

3 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (2)
Early P 1 (1)
P 1 (5)
P 2 (2)
P 4 (3)

Trial Status

Completed9
Active Not Recruiting2
Recruiting1
Withdrawn1
Not Yet Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT07506967Not ApplicableNot Yet RecruitingPrimary

Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers

NCT05185258Phase 4Active Not Recruiting

Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study

NCT02518048Phase 2CompletedPrimary

A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris

NCT02379793Phase 1CompletedPrimary

Skin Irritation Test of LEO 80185 Gel in Healthy Japanese Subjects

NCT02355639Phase 1CompletedPrimary

A Single-Centre Clinical Trial to Assess Steroid Induced Skin Atrophy on Healthy Skin

NCT02416258Phase 2CompletedPrimary

A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)

NCT06427889Phase 4Recruiting

Treatment Effects of Two Pharmaceutical Skin Care Creams for Xerotic Feet Among Persons with Diabetes

NCT05525741Not ApplicableActive Not RecruitingPrimary

Assessment of Circulating Fubctional Mitochondrias in Vitiligo Patients

NCT04971200Early Phase 1CompletedPrimary

Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo

NCT03196115Withdrawn

Biomarker for Hyaline Fibromatosis Syndrome (BioHFS)

NCT02985437Phase 1CompletedPrimary

Safety and Tolerability of Topically Applied Bovine Lung Surfactant on Intact Skin

NCT01764594Phase 1Completed

Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus

NCT01093911Phase 1Completed

Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)

NCT00147511Phase 4Completed

Time To Efficacy and Onset Of Action Of Linezolid

Showing all 14 trials

Research Network

Activity Timeline